Amir London, CEO of Kamada Pharmaceuticals, was recently a guest on Benzinga's All-Access.<br /><br />Kamada is a global biopharmaceutical company with a portfolio of assets indicated for rare and serious conditions. The company reports it is a leader in the specialty plasma-derived field, focused on diseases with limited treatment alternatives.<br /><br />Mr. London was on the program to discuss exciting developments in the company's development pipeline as well as Mr. London's strategy for M&A.
